A lower-priced version of blockbuster Remicade hasn’t sold well; will an even cheaper drug upend the obscure pricing of the drug industry?
Google’s sharp jump in paid clicks came at a high cost. Traffic acquisition spending outpaced revenue growth for the first time in five years.
Managing money for the rich looks like a better business than trading and investment banking: That is the upshot of half-year results for Swiss bank Julius Baer and the theme of last week’s U.S. bank results.
This was supposed to be the year Volkswagen drew a line under its diesel-emissions scandal. Instead the scandal seems to be spreading to the other German car giants.
The European Central Bank has reached the same spot the Federal Reserve reached four years ago. For financial markets on both sides of the Atlantic, it is an event that comes with consequences.
After years of overinvestment, which helped to sink global prices for steel, aluminum and other products, some of the worst-offending sectors in China are looking a bit better.
The cloud computing business is growing, and revenue is building even without the draw of price cuts.
Capital One sees default rates declining after a worrying jump, but investors should stay skeptical.
BHP has written off billions in U.S. shale investments, but it is poised to plow a substantial amount of funds into potassium fertilizer, or potash. Activist shareholder Elliott is kicking up a fuss.